CASI Pharmaceuticals, Inc.
CASIF- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001962738
No open-market purchases or sales by CASI Pharmaceuticals, Inc. insiders were filed in the last 90 days; 1 institution reported holding it in 13F filings for Q2 2026, worth $17 in total; no superinvestor holds it.
Holders of 5% or more of CASIF
Holders whose latest Schedule 13D or 13G filing reports 5% or more of CASI Pharmaceuticals, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| He Wei-Wu | 13D/A | 58.80%24.0M shares | +5.80 ppfrom 53.00% | Apr 18, 20238 filings | May 18, 2026 | SEC |
| Panacea Innovation Ltd | 13D/A | 22.50%4.65M shares | +2.60 ppfrom 19.90% | Sep 26, 20252 filings | Dec 17, 2025 | SEC |
| Huang James | 13G/A | 13.80%2.16M shares | – | Apr 10, 20236 filings | Jul 23, 2025 | SEC |
| Chen Zhenfeng M | 13G | 11.00%2.26M shares | New | Nov 26, 20251 filing | Nov 26, 2025 | SEC |
| Venrock Healthcare Capital Partners III, L.P. | 13G/A | 9.20%1.99M shares | – | Feb 17, 20261 filing | Feb 17, 2026 | SEC |
| Sparkle Byte Ltd | 13D/A | 5.00%1.02M shares | – | Jan 20, 20261 filing | Jan 20, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
25 Schedule 13D and 13G filings on CASI Pharmaceuticals, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| May 18, 20264:30 PM ET | He Wei-Wuand 6 others | 13D/A | 58.80%24.0M shares | +5.80 ppfrom 53.00% | May 18, 2026 | SEC |
| Mar 23, 20266:40 AM ET | He Wei-Wuand 6 others | 13D/A | 53.00%19.0M shares | +7.60 ppfrom 45.40% | Mar 23, 2026 | SEC |
| Feb 17, 20266:04 PM ET | Venrock Healthcare Capital Partners III, L.P.and 6 others | 13G/A | 9.20%1.99M shares | – | Dec 31, 2025 | SEC |
| Feb 13, 20266:03 PM ET | Foresite Capital Fund VI LPand 2 others | 13G/A | 0.00%0 shares | −6.30 ppfrom 6.30%Below 5% | Dec 31, 2025 | SEC |
| Feb 10, 20266:01 AM ET | He Wei-Wuand 6 others | 13D/A | 45.40%14.0M shares | +10.60 ppfrom 34.80% | Feb 9, 2026 | SEC |
| Jan 29, 20267:21 PM ET | He Wei-Wuand 6 others | 13D/A | 34.80%8.97M shares | +15.70 ppfrom 19.10% | Jan 27, 2026 | SEC |
| Jan 20, 20269:33 AM ET | Ho Chi Singand 5 others | 13D/A | 4.80%992.6K shares | −1.60 ppfrom 6.40%Below 5% | Sep 30, 2025 | SEC |
| Jan 20, 20269:30 AM ET | Sparkle Byte Ltdand 11 others | 13D/A | 5.00%1.02M shares | – | Sep 30, 2025 | SEC |
| Jan 9, 20266:03 AM ET | He Wei-Wuand 5 others | 13D/A | 19.10%3.97M shares | 0.00 ppfrom 19.10% | Jan 9, 2026 | SEC |
| Dec 18, 20256:01 AM ET | He Wei-Wuand 5 others | 13D/A | 19.10%3.97M shares | −4.70 ppfrom 23.80% | Dec 18, 2025 | SEC |
| Dec 17, 20254:15 PM ET | Panacea Innovation Ltdand 3 others | 13D/A | 22.50%4.65M shares | +2.60 ppfrom 19.90% | Dec 16, 2025 | SEC |
| Nov 26, 20254:05 PM ET | Chen Zhenfeng M | 13G | 11.00%2.26M shares | New | Sep 30, 2025 | SEC |
| Nov 14, 20254:05 PM ET | Foresite Capital Fund VI LPand 2 others | 13G/A | 6.30%980.0K shares | +1.20 ppfrom 5.10% | Sep 30, 2025 | SEC |
| Sep 26, 20256:45 PM ET | Panacea Innovation Ltdand 3 others | 13D | 19.90%3.66M shares | New | Sep 26, 2025 | SEC |
| Aug 12, 20254:05 PM ET | Foresite Capital Fund VI LPand 2 others | 13G/A | 5.10%787.1K shares | – | Jun 30, 2025 | SEC |
| Jul 23, 20259:39 AM ET | Huang Jamesand 3 others | 13G/A | 13.80%2.16M shares | – | Jun 30, 2025 | SEC |
| Jun 20, 20254:30 PM ET | He Wei-Wuand 5 others | 13D/A | 23.80%3.74M shares | – | Jun 16, 2025 | SEC |
| Feb 3, 20258:17 PM ET | Ho Chi Singand 5 others | 13D/A | 6.40%992.6K shares | – | Dec 30, 2024 | SEC |
| Oct 29, 2024 | Huang James | 13G/AOld format | – | – | – | SEC |
| Aug 12, 2024 | He Wei-Wu | 13D/AOld format | – | – | – | SEC |
| Jul 25, 2024 | Venrock Healthcare Capital Partners III, L.P. | 13GOld format | – | New | – | SEC |
| Jun 20, 2024 | Foresite Capital Fund VI LP | 13GOld format | – | New | – | SEC |
| Jun 11, 2024 | Huang James | 13G/AOld format | – | – | – | SEC |
| Jan 26, 2024 | Huang James | 13G/AOld format | – | – | – | SEC |
| Nov 9, 2023 | Huang James | 13G/AOld format | – | – | – | SEC |
| Jun 23, 2023 | Huang James | 13G/AOld format | – | – | – | SEC |
| Apr 18, 2023 | He Wei-Wu | 13D/AOld format | – | – | – | SEC |
| Apr 10, 2023 | Huang James | 13GOld format | – | New | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell CASI Pharmaceuticals, Inc. shares.
No Form 144 notices for CASI Pharmaceuticals, Inc. are on file.